康缘药业
(600557)
| 流通市值：71.51亿 | | | 总市值：71.51亿 |
| 流通股本：5.66亿 | | | 总股本：5.66亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 831,272,696.53 | 3,292,900,188.28 | 2,342,688,380.58 | 1,641,577,928.56 |
| 营业收入 | 831,272,696.53 | 3,292,900,188.28 | 2,342,688,380.58 | 1,641,577,928.56 |
| 二、营业总成本 | 741,531,883.69 | 3,025,881,463.99 | 2,141,450,228.75 | 1,488,675,905.49 |
| 营业成本 | 208,055,375.68 | 940,309,997.04 | 715,329,569.67 | 478,019,238.39 |
| 税金及附加 | 10,710,825.05 | 48,175,946.89 | 36,636,915.36 | 26,726,060.63 |
| 销售费用 | 318,306,986.05 | 1,117,496,356.57 | 806,936,366.24 | 571,377,252.05 |
| 管理费用 | 75,472,562.31 | 316,492,085.1 | 235,012,095.87 | 166,768,880.59 |
| 研发费用 | 128,935,424.84 | 607,612,625.54 | 351,637,702.25 | 246,565,004.87 |
| 财务费用 | 50,709.76 | -4,205,547.15 | -4,102,420.64 | -780,531.04 |
| 其中:利息费用 | 3,238,219.33 | 14,240,884.06 | 9,062,470.57 | 6,036,617.18 |
| 其中:利息收入 | 3,430,708.34 | 18,762,673.5 | 14,667,693.23 | 7,404,338.19 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 2,644,358.08 | 10,243,091.06 | 4,904,974.63 | 4,800,451 |
| 资产处置收益 | 32,604.34 | 429,202.97 | 421,945.72 | -20,480.39 |
| 资产减值损失(新) | - | -20,738,802.14 | - | - |
| 信用减值损失(新) | -2,579,683.94 | 1,323,842.03 | 246,304.98 | -1,157,749.8 |
| 其他收益 | 6,800,808.83 | 112,164,614.17 | 53,152,156.34 | 28,079,094.46 |
| 四、营业利润 | 96,638,900.15 | 370,440,672.38 | 259,963,533.5 | 184,603,338.34 |
| 加:营业外收入 | 3,726,794.18 | 3,308,603.14 | 833,441.5 | 301,626.74 |
| 减:营业外支出 | 2,753,022.83 | 17,183,174.83 | 7,655,125.64 | 4,122,557.37 |
| 五、利润总额 | 97,612,671.5 | 356,566,100.69 | 253,141,849.36 | 180,782,407.71 |
| 减:所得税费用 | 17,457,520.68 | 49,261,487.99 | 45,444,958.84 | 32,074,037.44 |
| 六、净利润 | 80,155,150.82 | 307,304,612.7 | 207,696,890.52 | 148,708,370.27 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 80,155,150.82 | 307,304,612.7 | 207,696,890.52 | 148,708,370.27 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 79,275,947.91 | 303,930,817.77 | 199,641,746.77 | 142,369,353.66 |
| 少数股东损益 | 879,202.91 | 3,373,794.93 | 8,055,143.75 | 6,339,016.61 |
| 扣除非经常损益后的净利润 | 72,023,546.28 | 217,261,934.69 | 160,124,620.74 | 119,995,673.79 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.14 | 0.54 | 0.35 | 0.25 |
| (二)稀释每股收益 | 0.14 | 0.54 | 0.35 | 0.25 |
| 九、综合收益总额 | 80,155,150.82 | 307,304,612.7 | 207,696,890.52 | 148,708,370.27 |
| 归属于母公司股东的综合收益总额 | 79,275,947.91 | 303,930,817.77 | 199,641,746.77 | 142,369,353.66 |
| 归属于少数股东的综合收益总额 | 879,202.91 | 3,373,794.93 | 8,055,143.75 | 6,339,016.61 |
| 公告日期 | 2026-04-30 | 2026-04-23 | 2025-10-31 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |